Andrographolide Ameliorates Atherosclerosis by Suppressing Pro-Inflammation and ROS Generation-Mediated Foam Cell Formation
- 5 Downloads
Inflammation, oxidative stress, and dyslipidemia are major factors in the pathogenesis of atherosclerosis. Andrographolide, a bioactive component of Andrographis paniculata, has several biological activities, including anti-inflammatory, antioxidant, and anticancer effects. This study shows that andrographolide downregulates the oxidized low-density lipoprotein (oxLDL)-induced expression of the pro-inflammatory molecules monocyte chemotactic protein (MCP)-1 and interleukin (IL)-6 and blocks the nuclear factor-κB signaling pathway in macrophages. Additionally, andrographolide treatment decreased reactive oxygen species (ROS) generation in oxLDL-induced macrophages, indicating that the compound can decrease oxidative stress. The results also suggest that andrographolide suppresses oxLDL-induced foam cell formation and inhibits oxLDL-induced CD36 expression in vitro. Furthermore, in vivo studies have indicated that andrographolide treatment ameliorates atherosclerosis pathogenesis in apolipoprotein E knockout mice. Therefore, by suppressing inflammation, ROS generation, and foam cell formation, andrographolide may ameliorate the progression of atherosclerosis, suggesting its potential as a therapeutic drug for the prevention and/or treatment of this disease.
KEY WORDSandrographolide atherosclerosis inflammation reactive oxygen species foam cell formation
The authors thank Editage [www.editage.cn] for the English language editing. We also thank Dr. Ying Liu from Guangdong Pharmaceutical University for providing good suggestion to experimental design and supporting parts of this project.
This work was supported by science and technology development grants from Nanjing Medical University (grant no. 2017NJMU012).;the Science and Technology Planning Project of Guangdong Province (2017A020211007), China; the Key Project of Natural Science Foundation of Guangdong Province (2016A030311014), China and the Natural Science Foundation of Guangdong Province (2015A030313582), China.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have are no conflicts of interest.
- 3.Collins, R., C. Reith, J. Emberson, J. Armitage, C. Baigent, L. Blackwell, R. Blumenthal, J. Danesh, G.D. Smith, D. DeMets, S. Evans, M. Law, S. MacMahon, S. Martin, B. Neal, N. Poulter, D. Preiss, P. Ridker, I. Roberts, A. Rodgers, P. Sandercock, K. Schulz, P. Sever, J. Simes, L. Smeeth, N. Wald, S. Yusuf, and R. Peto. 2016. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388: 2532–2561.CrossRefPubMedGoogle Scholar
- 13.Ji, X., C. Li, Y. Ou, N. Li, K. Yuan, G. Yang, X. Chen, Z. Yang, B. Liu, W.W. Cheung, L. Wang, R. Huang, and T. Lan. 2016. Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-kappaB pathway. Molecular and Cellular Endocrinology 437: 268–279.CrossRefPubMedGoogle Scholar
- 19.Al, B.R., F. Al-Bayaty, M.M. Al-Obaidi, S.F. Hussain, and T.Z. Mulok. 2014. Evaluation of the effect of andrographolide on atherosclerotic rabbits induced by Porphyromonas gingivalis. BioMed Research International 2014: 724718.Google Scholar
- 23.Li, Y., S. He, J. Tang, N. Ding, X. Chu, L. Cheng, X. Ding, T. Liang, S. Feng, S.U. Rahman, et al. 2017. Andrographolide inhibits inflammatory cytokines secretion in LPS-stimulated RAW264.7 cells through suppression of NF-kappaB/MAPK signaling pathway. Evidence-based Complementary and Alternative Medicine 2017: 8248142.PubMedPubMedCentralGoogle Scholar
- 29.Kunjathoor, V.V., M. Febbraio, E.A. Podrez, K.J. Moore, L. Andersson, S. Koehn, J.S. Rhee, R. Silverstein, H.F. Hoff, and M.W. Freeman. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. The Journal of Biological Chemistry 277: 49982–49988.CrossRefPubMedGoogle Scholar